Due to Vifor Pharma’s continued growth, we are now looking for an experienced Market Access Professional to drive our market access activities and support the commercial success of our products in the Benelux. Based in our Breda, Netherlands office, you will be responsible for the alignment of innovative and value added offers across key therapeutic areas with the needs of the changing health systems and our business approach in Belgium and the Netherlands. You will actively support the commercial objectives of the countries, with particular focus on Belgium, though the development and execution of Vifor Pharma’s market access commercial strategies and projects. Reporting to the Benelux GM and leading a team within this important, newly created role your tasks and responsibilities will include, but not be limited to:
As the new Market Access Professional for Vifor Pharma’s Benelux region, you will bring a university degree in business or life science related discipline as well as the following qualifications and experience:
Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions. The company’s goal is to be a global leader in iron deficiency, nephrology and cardio-renal therapies and strives to help patients around the world with severe and chronic diseases to lead better, healthier lives. Vifor Pharma Group has production sites in Switzerland and Portugal as well as a dynamic network of affiliates and partners offering broad market coverage all over the world. The company has an ever-growing global presence while at the same time remaining firmly rooted in its home market, Switzerland.
Vifor Pharma Group consists of Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, its joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
For more information, please visit: http://www.viforpharma.com/en/about-vifor-pharma/who-we-are.